Tofacitinib reduced inflammatory markers and improved selected skin conditions in a Phase 2 Down syndrome trial, while cognitive findings remain exploratory.
Written By: Malavatu Satvika, PharmD
Reviewed By: Dr. Abhijeet Ghangale,
MBBS, MS-General Surgery,
MCh – Neurosurgery
Researchers at the University of Colorado Anschutz reported findings from a Phase 2 trial of tofacitinib in adolescents and adults with Down syndrome and inflammatory skin conditions. Published in Cell Reports Medicine on November 17, 2026, the study evaluated whether Janus kinase (JAK) inhibition could reduce immune overactivity associated with trisomy 21. The trial met its predefined safety endpoint and demonstrated reductions in inflammatory markers, alongside improvements in selected skin conditions. Neuropsychological changes were preliminary and do not establish cognitive benefit.
Reduced Inflammatory Signalling and Skin Disease Activity
Blood analyses showed significant reductions in interferon activity, inflammatory cytokine scores and inflammation-associated metabolites, including quinolinic acid, a kynurenine pathway metabolite with neurotoxic properties. These findings indicate that tofacitinib modified several components of the inflammatory profile associated with Down syndrome.
Analyses of gene expression, circulating proteins and metabolites further showed changes in specific inflammatory pathways without evidence of overt immune suppression. Several abnormal inflammatory markers moved closer to levels observed in people without Down syndrome. However, these biomarker changes demonstrate biological activity and do not independently establish improvements in neurological function or prevention of long-term complications.
Clinical improvements were reported in immune-mediated skin conditions, particularly hidradenitis suppurativa and alopecia areata. Investigators assessed dermatological outcomes using standardized clinical scores and dermatology-related quality-of-life measures. Although these findings suggest potential clinical activity, improvements should not be generalized to all skin conditions included in the trial.
Phase 2 Trial Design and Patient Population
The study was a single-site, open-label, single-arm Phase 2 trial (NCT04246372) involving 47 participants aged 12–50 years with Down syndrome and inflammatory skin conditions. Eligible conditions included hidradenitis suppurativa, alopecia areata, psoriasis, atopic dermatitis and vitiligo.
Participants received oral tofacitinib at 5 mg twice daily for 16 weeks, with an optional extension to week 40. The trial included safety monitoring, dermatological evaluations, blood-based molecular analyses and neuropsychological assessments.
The two primary outcome measures were safety and reduction in whole-blood interferon transcriptional scores. The predefined safety endpoint allowed no more than two serious adverse events definitely attributable to tofacitinib during the 16-week treatment period among the planned 40 participants. The interferon endpoint assessed changes in transcriptional scores from baseline.
The absence of a placebo or active-control group remains a central limitation. Consequently, treatment effects cannot be reliably separated from natural disease fluctuations, concurrent care or other influences. The findings therefore provide evidence of biological activity and potential clinical benefit rather than definitive proof of efficacy.
Tofacitinib Targets the JAK-STAT Pathway
Down syndrome results from an additional copy of chromosome 21, which contains genes encoding several interferon receptors. Increased expression of these receptors contributes to heightened interferon signalling and widespread immune dysregulation.
Interferons and other cytokines activate intracellular signalling pathways involving Janus kinases and signal transducers and activators of transcription (STATs), which regulate inflammatory gene expression and immune-cell activity. Persistent activation may contribute to autoimmune and inflammatory manifestations.
Tofacitinib inhibits JAK1 and JAK3, interrupting signalling from multiple cytokines involved in immune activation. The study investigated whether this approach could reduce excessive immune signalling without causing overt suppression of normal immune responses. The molecular findings support this therapeutic rationale but do not indicate reversal of the underlying genetic condition.
Neurobehavioral Findings and Safety
Investigators also reported changes in selected assessments of attention, memory, vocabulary and behaviour, alongside improvements in some participant- and caregiver-reported measures of well-being. These observations may inform further research into the relationship between immune activity and brain health.
However, the neuropsychological findings remain exploratory. Repeated testing can produce practice effects, while the absence of a comparison group prevents investigators from attributing these changes directly to treatment. The results do not establish cognitive improvement or reduced Alzheimer’s disease risk.
The trial met its predefined safety endpoint, with a reported safety profile similar to that observed in the general population. Although reassuring, this finding does not eliminate the known risks associated with JAK inhibitors. The relatively small study population also limits the assessment of uncommon adverse events, making longer-term safety evaluation necessary.
Clinical Implications
The findings provide evidence that tofacitinib can modify inflammatory activity in people with Down syndrome and may improve selected immune-mediated skin conditions. The alignment between blood-based molecular changes and dermatological observations strengthens the rationale for further investigation.
However, the open-label, single-arm design limits causal interpretation of the clinical outcomes. Randomized, placebo-controlled trials are needed to confirm dermatological and other clinical benefits, identify participants most likely to respond and establish longer-term safety.
Tofacitinib is not approved specifically for Down syndrome, and the current findings do not establish a general treatment recommendation.
References
Rachubinski AL, et al. A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. Cell Reports Medicine. 2026;7(11):103138. Read the original research paper.
University of Colorado Anschutz. New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical Trial. November 18, 2026. Read the university announcement.
ClinicalTrials.gov. Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome. NCT04246372. View trial registration.
About the Writer
Malavatu Satvika (Linkedin) is a Pharm.D professional and aspiring healthcare medical writer with clinical exposure and research experience. Her interests include medical writing, drug safety, pharmaceutical research, and evidence-based healthcare communication. She has contributed to two research publications in pharmaceutical journals and hasMalavatu, gained practical experience in prescription review, patient counselling, medication review, adverse drug reaction monitoring, drug information services, literature review, and clinical documentation through regular hospital training.
She has completed certifications in clinical research, ICH-GCP E6(R3), data management for clinical research, and congenital hypothyroidism. With a strong foundation in pharmacy, clinical practice, and scientific research, she aims to translate complex medical and pharmaceutical information into accurate, clear, and evidence-based healthcare content. She is also preparing to pursue a PhD and further develop her expertise in medical writing and pharmaceutical research.
